Clinical Trials Logo
  1. Home
  2. Pulmonary Sarcoidosis
  3. NCT05415137

Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

Pulmonary Sarcoidosis Clinical Trial

Official title:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

Clinical Trial Summary

This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment. This study will enroll adults with histologically confirmed pulmonary sarcoidosis receiving stable treatment with oral corticosteroid (OCS), with or without immunosuppressant therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05415137
Study type Interventional
Source aTyr Pharma, Inc.
Contact aTyr Pharma Clinical Research
Phone 877-215-5731
Email clinicaltrials@atyrpharma.com
Status Recruiting
Phase Phase 3
Start date September 15, 2022
Completion date January 15, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT04064242 - Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis Phase 2
Terminated NCT00262132 - Mycophenolate for Pulmonary Sarcoidosis Phase 3
Recruiting NCT00001532 - Role of Genetic Factors in the Development of Lung Disease
Completed NCT04318392 - Breath Analysis in Patients With Suspected Sarcoidosis: The VOCs-IS Study
Active, not recruiting NCT03755245 - Biodistribution, Dosimetry and Performance of [68Ga]Ga-DOTA-Siglec-9 in Healthy and Patients With Rheumatoid Arthritis, Vasculitis or Pulmonary Sarcoidosis N/A
Completed NCT01587001 - The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis N/A
Recruiting NCT05890729 - A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis Phase 1/Phase 2
Recruiting NCT02824419 - Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis Phase 2/Phase 3
Recruiting NCT06205121 - Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis Phase 2
Completed NCT02200146 - Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). Phase 3
Terminated NCT01732211 - A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis Phase 2
Enrolling by invitation NCT06169397 - An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis Phase 2
Active, not recruiting NCT05368883 - Comparison of the Effects of One-Legged and Two-Legged Exercise Training on Exercise Capacity and Fatigue in Patients With Sarcoidosis N/A
Not yet recruiting NCT05247554 - Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis Phase 3
Completed NCT03599414 - CASPA: CArdiac Sarcoidosis in PApworth
Recruiting NCT02188017 - Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS) Phase 4
Recruiting NCT06113991 - Study Comparing Chronic Beryllium Disease to Pulmonary Sarcoidosis
Completed NCT01169038 - Investigation of the Efficacy of Antibiotics on Pulmonary Sarcoidosis Phase 1
Completed NCT00701207 - Study of Nicotine Patches in Patients With Sarcoidosis Early Phase 1
Completed NCT03824392 - Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis Phase 1/Phase 2